Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
GeoVax Labs
GOVX
GeoVax Labs
Regulatory Advances And Pipeline Expansion Will Unlock Future Potential
AN
AnalystConsensusTarget
Not Invested
Consensus Narrative from 4 Analysts
Published
07 May 25
Updated
15 Aug 25
12
Set Fair Value
0
votes
Share
AnalystConsensusTarget
's Fair Value
US$10.38
92.6% undervalued
intrinsic discount
15 Aug
US$0.77
Loading
1Y
-88.0%
7D
0.9%
Author's Valuation
US$10.4
92.6% undervalued
intrinsic discount
AnalystConsensusTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystConsensusTarget Fair Value
US$10.4
92.6% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-102m
423m
2014
2017
2020
2023
2025
2026
2028
Revenue US$422.6m
Earnings US$225.8m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
60.17%
Biotech revenue growth rate
11.97%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$225.82m
Earnings '28
x
3.12x
PE Ratio '28
=
US$703.70m
Market Cap '28
US$703.70m
Market Cap '28
/
55.72m
No. shares '28
=
US$12.63
Share Price '28
US$12.63
Share Price '28
Discounted to 2025 @ 6.78% p.a.
=
US$10.38
Fair Value '25